229 related articles for article (PubMed ID: 34578259)
21. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
22. Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma.
Verheije MH; Lamfers ML; Würdinger T; Grinwis GC; Gerritsen WR; van Beusechem VW; Rottier PJ
J Virol; 2009 Aug; 83(15):7507-16. PubMed ID: 19439466
[TBL] [Abstract][Full Text] [Related]
23. Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.
Nakashima H; Nguyen T; Kasai K; Passaro C; Ito H; Goins WF; Shaikh I; Erdelyi R; Nishihara R; Nakano I; Reardon DA; Anderson AC; Kuchroo V; Chiocca EA
Clin Cancer Res; 2018 Jun; 24(11):2574-2584. PubMed ID: 29511029
[No Abstract] [Full Text] [Related]
24. The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies.
Bernstock JD; Hoffman SE; Chen JA; Gupta S; Kappel AD; Smith TR; Chiocca EA
Viruses; 2021 Jun; 13(6):. PubMed ID: 34204248
[TBL] [Abstract][Full Text] [Related]
25. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma.
Ahmed AU; Thaci B; Alexiades NG; Han Y; Qian S; Liu F; Balyasnikova IV; Ulasov IY; Aboody KS; Lesniak MS
Mol Ther; 2011 Sep; 19(9):1714-26. PubMed ID: 21629227
[TBL] [Abstract][Full Text] [Related]
26. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
[TBL] [Abstract][Full Text] [Related]
27. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
Workenhe ST; Pol JG; Lichty BD; Cummings DT; Mossman KL
Cancer Immunol Res; 2013 Nov; 1(5):309-19. PubMed ID: 24777969
[TBL] [Abstract][Full Text] [Related]
28. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate.
Chen Q; Wu J; Ye Q; Ma F; Zhu Q; Wu Y; Shan C; Xie X; Li D; Zhan X; Li C; Li XF; Qin X; Zhao T; Wu H; Shi PY; Man J; Qin CF
mBio; 2018 Sep; 9(5):. PubMed ID: 30228241
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic measles virus retargeting by ligand display.
Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.
Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A
J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187
[TBL] [Abstract][Full Text] [Related]
34. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
35. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.
Kaur B; Chiocca EA; Cripe TP
Curr Pharm Biotechnol; 2012 Jul; 13(9):1842-51. PubMed ID: 21740359
[TBL] [Abstract][Full Text] [Related]
37. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.
Wollmann G; Ozduman K; van den Pol AN
Cancer J; 2012; 18(1):69-81. PubMed ID: 22290260
[TBL] [Abstract][Full Text] [Related]
38. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
Allen C; Vongpunsawad S; Nakamura T; James CD; Schroeder M; Cattaneo R; Giannini C; Krempski J; Peng KW; Goble JM; Uhm JH; Russell SJ; Galanis E
Cancer Res; 2006 Dec; 66(24):11840-50. PubMed ID: 17178881
[TBL] [Abstract][Full Text] [Related]
39. [Development of conditionally replicating oncolytic HSV vector--targeted gene therapy for sarcoma by oncolytic viruses].
Takahashi K; Yamamura H
Nihon Rinsho; 2006 Mar; 64 Suppl 3():326-33. PubMed ID: 16615493
[No Abstract] [Full Text] [Related]
40. Tepilamide Fumarate as a Novel Potentiator of Virus-Based Therapy.
Alwithenani A; Arulanandam R; Wong B; Spinelli MM; Chen A; Maznyi G; Gilchrist VH; Alain T; Diallo JS
Viruses; 2024 Jun; 16(6):. PubMed ID: 38932212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
